SalaryGuide
AboutPricingFor Employers

Marketing jobs

9 marketing jobs

Ipsen logo
7 days ago

Director, Portfolio Communications & Advocacy Relations

Ipsen

Cambridge, MA (On-site)Full time$177K/yr – $245K/yr
Ipsen logo
7 days ago

Director, HCP Marketing, Bylvay

Ipsen

Cambridge, MA (On-site)Full time$191K/yr – $265K/yr
Ipsen logo
4 weeks ago

Associate Director, HCP Marketing, Rare Disease Business Unit

Ipsen

Cambridge, MA (On-site)Full time$194K/yr – $225K/yr
IPSEN logo
5 weeks ago

Associate Director, HCP Marketing, Rare Disease / PBC

IPSEN

Cambridge, MA (Unknown)Full time$194K/yr – $220K/yr
Ipsen logo
5 weeks ago

Associate Director, HCP Marketing, Rare Disease / PBC

Ipsen

Cambridge, MA (On-site)Full time$194K/yr – $220K/yr
Ipsen logo
2 months ago

Global Brand Lead, Dysport - Migraine

Ipsen

Cambridge, MA (Hybrid)Full time$233K/yr – $310K/yr
Ipsen logo
3 months ago

Global Brand Lead, Migraine

Ipsen

Cambridge, MA (Hybrid)Full time$233K/yr – $341K/yr
Ipsen logo
3 months ago

Director, Value & Access Marketing and Strategy, Oncology

Ipsen

Cambridge, MA (Hybrid)Full time$191K/yr – $260K/yr
Ipsen logo
4 months ago

VIE - US Rare Disease Brand Manager

Ipsen

Boston, MA (On-site)Full time

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

9 jobs
Ipsen logo

Director, Portfolio Communications & Advocacy Relations

Ipsen

Cambridge, MA (On-site)

$177K/yr - $245K/yrIn-houseFull-timeDirector/executive12+ years exp.
7 days ago
Ipsen logo

Director, HCP Marketing, Bylvay

Ipsen

Cambridge, MA (On-site)

$191K/yr - $265K/yrIn-houseFull-timeSenior level12+ years exp.
7 days ago
Ipsen logo

Associate Director, HCP Marketing, Rare Disease Business Unit

Ipsen

Cambridge, MA (On-site)

$194K/yr - $225K/yrIn-houseFull-timeSenior level10+ years exp.
4 weeks ago
IPSEN logo

Associate Director, HCP Marketing, Rare Disease / PBC

IPSEN

Cambridge, MA (Unknown)

$194K/yr - $220K/yrIn-houseFull-timeSenior level10+ years exp.
5 weeks ago
Ipsen logo

Associate Director, HCP Marketing, Rare Disease / PBC

Ipsen

Cambridge, MA (On-site)

$194K/yr - $220K/yrIn-houseFull-timeSenior level10+ years exp.
5 weeks ago
Ipsen logo

Global Brand Lead, Dysport - Migraine

Ipsen

Cambridge, MA (Hybrid)

$233K/yr - $310K/yrIn-houseFull-timeSenior level15+ years exp.
2 months ago
Ipsen logo

Global Brand Lead, Migraine

Ipsen

Cambridge, MA (Hybrid)

$233K/yr - $341K/yrIn-houseFull-timeSenior level15+ years exp.
3 months ago
Ipsen logo

Director, Value & Access Marketing and Strategy, Oncology

Ipsen

Cambridge, MA (Hybrid)

$191K/yr - $260K/yrIn-houseFull-timeDirector/executive12+ years exp.
3 months ago
Ipsen logo

VIE - US Rare Disease Brand Manager

Ipsen

Boston, MA (On-site)

In-houseFull-timeMid level
4 months ago
Ipsen logo
Ipsen

Director, Portfolio Communications & Advocacy Relations

Cambridge, MA (On-site)

$177K/yr – $245K/yrDirector/Executive12+ years expFull time

Posted 7 days ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Owns and leads corporate affairs strategy across multiple therapeutic areas and launches, guiding integrated communications, launch readiness, stakeholder engagement and issue management with global alignment for the North American market.

  • Own strategy and execution of corporate communications across multiple brands and future launches
  • Advise senior leaders and cross-functional teams to influence business and reputation outcomes
  • Drive multichannel programs, launch readiness and proactive issue management across North America

Job Description

Responsibilities

  • Provide strategic leadership for Corporate Affairs across multiple therapeutic areas, in-market brands and future launches, ensuring communications strategies directly support business objectives, growth priorities and corporate reputation goals
  • Serve as a trusted advisor to executive leadership, brand teams and cross-functional stakeholders, influencing key business decisions through strategic communications counsel and stakeholder insights
  • Lead the development and execution of integrated communications and advocacy strategies that drive awareness, engagement and differentiation across Ipsen's portfolio with clear measurement of business and reputational outcomes
  • Shape launch readiness and commercialization strategies by embedding Corporate Affairs into launch planning, market preparation, stakeholder engagement and reputation management activities
  • Identify emerging opportunities, risks and marketplace dynamics, proactively developing strategies that protect and strengthen Ipsen's reputation while supporting organizational priorities
  • Drive enterprise-wide alignment across Corporate Affairs, Commercial, Medical Affairs, Market Access, Regulatory, Legal and other relevant teams to ensure a unified stakeholder engagement approach
  • Create and implement innovative, multichannel communications programs that leverage multiple channels and platforms to maximize reach, engagement and impact
  • Cultivate and maintain strategic relationships with external stakeholders to advance disease education, patient support and Ipsen's corporate reputation
  • Partner closely with global Corporate Affairs to ensure alignment of global priorities while tailoring execution to the North American market
  • Anticipate and lead responses to complex issues, sensitive stakeholder situations, and reputational challenges, providing strategic guidance to senior leadership and ensuring preparedness through scenario planning.

Requirements

  • 12-15+ years of progressive experience in biopharmaceutical, healthcare, or healthcare communications environments, including significant experience leading product communications, advocacy relations and launch communications
  • Demonstrated success partnering with senior executives and influencing strategic business decisions through communications leadership
  • Proven track record developing and leading integrated communications strategies that deliver measurable business, reputational and stakeholder engagement outcomes
  • Deep understanding of the North American healthcare landscape, patient advocacy environment, media ecosystem and pharmaceutical company dynamics
  • Experience leading complex cross-functional initiatives, major product launches, issues management and reputation-building programs in a highly matrixed organization
  • Bachelor's degree required
  • Advanced degree in Communications, Public Relations, Journalism, Business, Public Health, or related field preferred
  • English

Benefits

  • This job is eligible to participate in our short-term incentives program. At Ipsen we are proud to offer a comprehensive employee benefits package, including 401(k) with company contributions, group medical, dental and vision coverage, life and disability insurance, short- and long-term disability insurance, as well as flexible spending accounts. Ipsen also provides parental leave, paid time off, a discretionary winter shutdown, well-being allowance, commuter benefits, and much more.
Ipsen logo

Ipsen

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in 88 countries.For more information, visit ipsen.com.Pauta exclusiva para México:Clave de Autorización COFEPRIS: 243300201B1962 CONSULTE A SU MÉDICO.

Founded in 1987
Paris, Île-de-France, FRA
6.5K employees (363 in marketing)
www.ipsen.com

Traffic Signals

Monthly Visitors
90.3K
Traffic Source Mix
Search
57.1%
Direct
32.9%
Referral
6.6%
Social
2%
Paid
1.1%

Headcount Trend

Current headcount: ~6.5K

Marketing Team

Marketing Team Size
311 (5% of company)
Median Career Experience
14 years
Median Tenure
3 years
Marketing Roles Posted (Last 30 Days)
4

People

Marketing Leadership

Jérôme de Larosière
Jérôme de Larosière
VP Marketing Rare Disease, North America
At the company for 9 years 7 months
Jennifer English
Jennifer English
Value & Access Chief of Staff and Head Strategic Pricing, Marketing and Operations at Ipsen
At the company for 4 years 6 months
Katherine Lai
Head of Marketing
At the company for 5 years 7 months
Edith Windsor
Edith Windsor
Director, US Patient Marketing, Primary Biliary Cholangitis PBC
At the company for 1 year 7 months

Funding

Total Funding
$574.7M
Last Raise
$545.6M
Post IPO Debt, 12 months ago

Funding History

  • Mar 2025
    Post IPO Debt • $545.6M
  • Nov 2017
    Post IPO Equity • $29.1M

Recent News

ESMO 2025 : les données d’Ipsen enrichissent et élargissent son portefeuille de produits en R&D et commercialisés en Oncologie - Global
Oct 13, 2025 • Ipsen
Ipsen: UBS réitère son conseil à achat
Oct 13, 2025 • Boursorama
Envie d’une carrière dans la pharma ? Ipsen vous offre des carrières sur-mesure - L’interview de Laurent Bertocchi
Sep 30, 2025 • Monde des grandes écoles
Ipsen et BioLabs Hôtel-Dieu décernent le Golden Ticket Ipsen 2025 à DETERA Therapeutics
Sep 26, 2025 • Boursorama
Ipsen : Prises de bénéfices sur le turbo PUT 74U2S (+15.46%)
Sep 23, 2025 • La Tribune
Ipsen : des données encourageantes pour IPN10200
Sep 22, 2025 • Boursorama
Ipsen : L'essai de Phase II LANTIC en esthétique démontre un profil clinique différencié à longue durée d'action, premier de sa classe pour l'IPN10200, permettant le lancement de l'étude de Phase III
Sep 22, 2025 • Boursier.com
L’essai de Phase II LANTIC d’Ipsen en esthétique démontre
Sep 22, 2025 • GlobeNewswire
L’IPN10200 d’Ipsen montre des résultats prometteurs dans un essai esthétique de phase II
Sep 22, 2025 • Investing.com France
Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III
Sep 22, 2025 • Ipsen Pharma
Ipsen’s IPN10200 shows promising results in Phase II aesthetics trial
Sep 22, 2025 • Investing.com
Ipsen shares first aesthetic data for IPN10200 in phase II trial
Sep 22, 2025 • MarketScreener
Ipsen : le produit Bylvay approuvé au Japon dans une indication
Sep 19, 2025 • Boursorama
Ipsen obtient le feu vert au traitement d'une maladie rare du foie au Japon
Sep 19, 2025 • Les Echos
Ipsen announces Bylvay approval in Japan for pruritus associated with PFIC
Sep 19, 2025 • thefly.com
Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC
Sep 19, 2025 • Ipsen Pharma
Regeneron drug on track to be second FOP treatment
Sep 18, 2025 • pharmaphorum
Regeneron reports phase 3 win in ultrarare disease, bouncing back to spark race to FDA
Sep 17, 2025 • FierceBiotech
Chez Ipsen, Christelle Huguet poursuit sa quête de découvertes dans les sciences appliquées
Sep 16, 2025 • L'Usine Nouvelle
Ipsen : objectifs en vue
Sep 15, 2025 • Boursier.com
Long Regulatory Saga for Intercept Pharma Liver Drug Ends a Decade After Speedy FDA Approval
Sep 12, 2025 • MedCity News
Intercept pulls Ocaliva off the market in the US
Sep 11, 2025 • pharmaphorum
Health Canada Approves Bylvay™ (odevixibat) for the treatment of cholestatic pruritus in patients with Alagille Syndrome
Sep 9, 2025 • PR Newswire UK
Health Canada Approves Bylvay™ (odevixibat) for the treatment of cholestatic pruritus in patients with Alagille Syndrome Français
Sep 9, 2025 • Canada NewsWire
Health Canada Approves Bylvay™ (odevixibat) for the treatment of cholestatic pruritus in patients with Alagille Syndrome
Sep 9, 2025 • BioSpace
Chutes & Ladders—Merck KGaA lands new R&D chief
Sep 5, 2025 • FierceBiotech
Ipsen en pleine ascension face à une barrière technique majeure
Sep 4, 2025 • ABC Bourse
IPSEN : Encore du potentiel
Sep 4, 2025 • BFM Bourse
Ipsen : Correction technique attendue
Sep 3, 2025 • La Tribune
Parabilis Medicines Appoints Fawzi Benzaghou, M.D., as Chief Medical Officer
Sep 3, 2025 • PharmiWeb
Parabilis Medicines Appoints Fawzi Benzaghou, M.D., as Chief Medical Officer
Sep 3, 2025 • citybiz
IPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 2025
Sep 2, 2025 • Ipsen Pharma
IPSEN - Buy-back programme - Art 5 of MAR - Week 34 - 2025
Aug 29, 2025 • Ipsen Pharma
Zydus' phase 3 liver disease win tees up filing to challenge Gilead and Ipsen
Aug 29, 2025 • FierceBiotech
Cholestatic Pruritus Global and Regional Markets, 2023-2025 & 2025-2035 | Competition Intensifies as Pharma and Biotech Firms Pursue Partnerships, M&A, and Novel Therapy Development
Aug 27, 2025 • Research and Markets
Women In Bio Names Gina Ford First-Ever CEO
Aug 27, 2025 • PR Newswire
Ipsen - July 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
Aug 27, 2025 • Ipsen Pharma
Servier, Sanofi, Ipsen... Les laboratoires français décrochent trois nouvelles autorisations en Europe pour des traitements contre le cancer
Aug 25, 2025 • L'Usine Nouvelle
Made in France : Ipsen, d'une petite officine au troisième laboratoire pharmaceutique français
Aug 23, 2025 • L'Usine Nouvelle
Primary Biliary Cholangitis Therapeutics Global Market Report 2025| Business Growth, Current and Future Trends till 2029
Aug 22, 2025 • EIN Presswire
Ipsen relève ses objectifs 2025, hausse du CA au S1
Aug 19, 2025 • Les Echos
IPSEN - Buy-back programme - Art 5 of MAR - Week 33 - 2025
Aug 19, 2025 • Ipsen Pharma
Ipsen, son médicament phare, somatuline, bénéficie d'un sursis, l'annonce de nouveaux relais de croissance est attendue au second semestre
Aug 14, 2025 • Les Echos
Ipsen: RBC réitère son opinion 'surperformance', objectif 148 euros
Aug 12, 2025 • ABC Bourse
IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2025
Aug 12, 2025 • Ipsen Pharma
Skeletal Dysplasia Market Growth Analysis 2025-2030 Featuring BioMarin Pharma, BridgeBio Pharma, Ascendis Pharma, Ipsen, QED Therapeutics and Other Major Players
Aug 12, 2025 • Research and Markets
Non-Surgical Aesthetic Device Market is Projected to Reach USD 6.5 Billion, with a Robust 5.4% CAGR Till 2035
Aug 12, 2025 • EIN Presswire
IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight
Aug 11, 2025 • PR Newswire UK
IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight
Aug 11, 2025 • PR Newswire
Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights
Aug 8, 2025 • BioSpace
Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights
Aug 7, 2025 • Sutro Biopharma, Inc.
Cap sur l’innovation à Dreux : Ipsen inaugure ses nouveaux laboratoires de développement précoce
Jul 31, 2025 • Ipsen
Ipsen relève ses objectifs financiers 2025 après un solide premier semestre
Jul 31, 2025 • Les Echos
L'action IPSEN chute de 7,25%
Jul 31, 2025 • Idéal Investisseur
Ipsen shares fall 6% as guidance raise overshadowed by product misses
Jul 31, 2025 • Investing.com
Ipsen posts strong second quarter, raises full-year guidance
Jul 31, 2025 • Pharma Letter
Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance
Jul 31, 2025 • Ipsen Pharma
Ipsen S.A. Reports Earnings Results for the Half Year Ended June 30, 2025
Jul 31, 2025 • MarketScreener
Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025)
Jul 31, 2025 • Ipsen Pharma
Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance
Jul 30, 2025 • Morningstar.com
Ipsen: l'UE approuve le Cabometyx contre certaines tumeurs
Jul 25, 2025 • Les Echos
Ipsen’s Cabometyx secures EC nod for neuroendocrine tumors
Jul 25, 2025 • Pharma Letter
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
Jul 25, 2025 • BioSpace
Botulinum Toxin Market to Reach USD 13.1 Billion, Globally, by 2031 at 8.6% CAGR: Allied Market Research
Jul 24, 2025 • EIN Presswire
Ipsen granted EU nod for Exelixis-partnered cancer drug for neuroendocrine tumors
Jul 24, 2025 • Seeking Alpha
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
Jul 24, 2025 • Ipsen Pharma
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
Jul 24, 2025 • BioSpace
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
Jul 24, 2025 • Morningstar.com
Ipsen annonce des changements au sein de son Comité Exécutif
Jul 23, 2025 • MyPharma Editions
Ipsen S.A. Announces New Appointments to Its Executive Committee
Jul 23, 2025 • MarketScreener
Ipsen announces changes to its Executive Committee
Jul 23, 2025 • BioSpace
Ipsen announces executive committee changes
Jul 23, 2025 • Pharma Letter
Ipsen announces changes to its Executive Committee
Jul 23, 2025 • Ipsen Pharma
Ipsen announces changes to its Executive Committee
Jul 22, 2025 • Morningstar.com
IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2025
Jul 22, 2025 • Ipsen Pharma
GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights
Jul 17, 2025 • Morningstar.com
GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights
Jul 17, 2025 • Spherix Global Insights
A Dreux, Ipsen inaugure deux laboratoires de développement précoce, au coeur d'une stratégie mondiale
Jul 12, 2025 • Actu.fr
Botulinum Toxins Market worth $15.7 billion by 2030 with 11.7% CAGR | MarketsandMarkets™
Jul 11, 2025 • prnewswire.co.uk
Ipsen - June 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
Jul 10, 2025 • GlobeNewswire News Room
Europe Pharmaceutical Drugs Market Expands with R&D Innovation, Biologics Growth, and Regulatory Harmonization 2025–2032
Jul 10, 2025 • EIN Presswire
The Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal and IRICoR Announce initiation of Phase 1 Trial of Licensed Small Molecule Therapy for Solid Tumors
Jul 8, 2025 • PR Newswire
The Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal and IRICoR Announce initiation of Phase 1 Trial of Licensed Small Molecule Therapy for Solid Tumors Français
Jul 8, 2025 • Canada NewsWire
IPSEN - Buy-back programme - Art 5 of MAR - Week 27- 2025
Jul 8, 2025 • GlobeNewswire News Room
Ipsen - Half year statement - 2025 06 30
Jul 8, 2025 • BioSpace
Ipsen - Half year statement - 2025 06 30
Jul 7, 2025 • GlobeNewswire News Room
Nomination Ipsen : Senior Director, CMC Regulatory Affairs, Biologics
Jul 5, 2025 • vd-communication.fr
Ipsen inaugure son nouveau siège social mondial à Paris
Jul 3, 2025 • Ipsen
Ipsen : inaugure son nouveau siège social mondial à Paris
Jul 2, 2025 • Boursier.com
IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2025
Jul 1, 2025 • Ipsen Pharma
Neurogenic Detrusor Overactivity Market Forecast To 2034 – For Business Leaders, Analysts, And Strategic Teams
Jul 1, 2025 • EIN Presswire
Dominique Bery, une stratège pour l’activité France d'Ipsen
Jun 28, 2025 • L'Usine Nouvelle
Alagille Syndrome Market Research 2025-2035 | Funding Activities, Mergers and Acquisitions, Regulatory Approvals, Partnerships, Collaborations and Business Expansions - ResearchAndMarkets.com
Jun 27, 2025 • Business Wire
IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2025
Jun 24, 2025 • Ipsen Pharma
Alagille Syndrome Market Research 2025-2035 | Competitive Analysis of Mirum Pharmaceuticals, Ipsen, and Takeda Pharmaceutical
Jun 24, 2025 • Research and Markets
Ipsen : avis positif du CHMP pour Cabometyx dans les tumeurs neuroendocrines avancées
Jun 23, 2025 • Boursier.com
Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars
Jun 23, 2025 • Benzinga.com
Bile Acid Transport Inhibitors (IBATs) Market to Reach $200 Million by 2025, Forecasted to Grow at 20% CAGR Through 2032 Amidst Rising Rare Liver Disease Incidence
Jun 23, 2025 • PharmiWeb
Ipsen se rapproche d'une autorisation en UE pour cabozantinib, son traitement contre certaines tumeurs
Jun 20, 2025 • Les Echos
Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
Jun 20, 2025 • BioSpace